Celltrion Sets Out Strategy For China
As Firm Announces Plans For A Biosimilar Launch Every Year
Celltrion has unveiled plans to construct a biologics plant in Wuhan, China, as well as setting up a direct sales network in the country, as part of its wider global strategy that also involves launching a new biosimilar every year to 2030.
